1,728 results on '"Kurata, T."'
Search Results
2. Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L)
3. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
4. EP11.03-08 Multicenter Pharmacokinetic Study of Pembrolizumab for Non-Small Cell Lung Cancer in Older Adults Aged Over 75 Years
5. EP06.02-05 Agreement among Programmed Cell Death Ligand-1 Immunohistochemistry Results Using 73-10, 22C3 and 28-8 Antibodies for Lung Cancer
6. Low-dose eribulin mesylate exerts antitumor effects in gastric cancer by inhibiting fibrosis via the suppression of epithelial–mesenchymal transition and acts synergistically with 5-fluorouracil
7. Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations
8. New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer
9. Évaluation de la résistance acquise au sotorasib dans le cancer colorectal (CCR) et le cancer bronchique non à petites cellules (CBNPC) avec mutation KRASG12C : analyse de biomarqueurs plasmatiques de l’étude CodeBreaK 100
10. 330P A real-world multi-center prospective observational study of atezolizumab (Atezo) + bevacizumab (Bev) + carboplatin (CBDCA) + paclitaxel (PTX) (ABCP) in patients (pts) with advanced EGFR-mutated (EGFRm) NSCLC after EGFR-TKIs failure
11. 1160P Survival impact of second-line immune checkpoint inhibitors in the elderly patients with advanced squamous non-small cell lung cancer: Post-hoc analysis from a CAPITAL study
12. 973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC
13. 1534P Phase II study of berzosertib + topotecan in patients with relapsed platinum (Pt)-resistant SCLC (DDRiver SCLC 250): Japanese safety run-in
14. MA06.04 Phase II Study of Durvalumab Plus Concurrent Radiotherapy in Unresectable Locally Advanced NSCLC: DOLPHIN Study (WJOG11619L)
15. EP08.02-115 A Retrospective, Multicenter, Observational Study to Evaluate Outcomes With Lorlatinib After Alectinib in ALK+ NSCLC in Japan
16. Mechanism of regulation and neutralization of tRNA-phosphorylating small RelA-SpoT homologue toxins
17. SO-39 Evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated colorectal cancer: Exploratory plasma biomarker analysis of CodeBreaK 100
18. P-78 A phase II study of resection followed by capecitabine plus oxaliplatin for liver metastasis of colorectal cancer (REX study): Final analysis
19. Characterization of EBV-Infected Epithelial Cell Lines from Gastric Cancer-Bearing Tissues
20. Pathway of viral spread in herpes zoster: detection of the protein encoded by open reading frame 63 of varicella-zoster virus in biopsy specimens
21. In vitro expansion of CD34+CD38− cells under stimulation with hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia
22. A retrospective study of pharmacotherapy on delirium in elderly hospitalised patients
23. Amino-Reductones : Formation Mechanisms and Structural Characteristics
24. 168TiP KEYNOTE-A86: Phase III, randomized, open-label study of first-line subcutaneous (SC) vs intravenous (IV) pembrolizumab with platinum doublet chemotherapy in metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC)
25. 6P Pembrolizumab plus chemotherapy vs chemotherapy in Asian patients with PD-L1 negative advanced NSCLC: Pooled analysis of KN021G, KN189 and KN407
26. MA02.05 A Phase I Study of Afatinib in Combination With Osimertinib in Patients After Failure of Prior Osimertinib
27. Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia
28. An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors
29. Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts: LBA1_PR
30. Is response rate increment obtained by molecular targeted agents related to survival benefit in the phase III trials of advanced cancer?
31. Viral Pathology of Human Herpesvirus 6 Infection
32. 1333P Dose and schedule modifications of carboplatin plus nab-paclitaxel for elderly patients with squamous non-small cell lung cancer from the CAPITAL study
33. 1292P Two single-arm, multicenter phase-II trials of PD-1 inhibitors in patients with pulmonary sarcomatoid carcinoma (NCCH1603/NCCH1703)
34. LBA66 Afatinib versus chemotherapy for treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation: A phase III study (ACHILLES/TORG1834)
35. 1482P Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in elderly adults aged over 75 years
36. P-206 Effects of eribulin mesilate for tumor progression and fibrosis in gastric cancer
37. Analysis of single-photon-detection characteristics of GaInAs/InP avalanche photodiodes
38. FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189
39. P21.01 Phase I Study of Carboplatin/Nab-Paclitaxel and Concurrent TRT in Elderly Patients with Unresectable Locally Advanced NSCLC
40. Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial
41. Spiders /
42. Two new species of Ontario spiders /
43. A faunal investigation of the Sault Ste. Marie region, Ontario /
44. Development of the Evans Wave Equation in the Weak-Field Limit: The Electrogravitic Equation
45. Characterization of Oita virus 296/1972 of Rhabdoviridae isolated from a horseshoe bat bearing characteristics of both lyssavirus and vesiculovirus
46. 387P Phase Ib study of savolitinib ± osimertinib in Japanese patients (pts) with advanced solid malignancies & EGFRm NSCLC: TATTON part C
47. Branched chain amino acids as source of specific branched chain volatile fatty acids during the fermentation process of fish sauce
48. Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice
49. A novel familial prion disease causing pan-autonomic-sensory neuropathy and cognitive impairment
50. Humanoid Robots in Waseda University—Hadaly-2 and WABIAN
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.